Evidence map›Paper›PMID 31844809›Full record

ArticleKidney international reports2019

Treatment Patterns Among Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN).

Michelle M O'Shaughnessy, Jonathan P Troost, Andrew S Bomback, Michelle A Hladunewich, Isa F Ashoor, Keisha L Gibson, Raed Bou Matar, David T Selewski, Tarak Srivastava, Michelle N Rheault and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Cellular and molecular interrogation of kidney biopsy specimens.Current opinion in nephrology and hypertension · 2022
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 19 institutions in 2 countries.

Michelle M O'ShaughnessyDivision of Nephrology, Stanford University School of Medicine, Palo Alto, California, USA.
Jonathan P TroostDivision of Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
Andrew S BombackDivision of Nephrology, Columbia University, New York, New York, USA.
Michelle A HladunewichDivision of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Isa F AshoorDivision of Nephrology, Department of Pediatrics, LSU Health and Children's Hospital, New Orleans, Louisiana, USA.
Keisha L GibsonUNC Kidney Center, Division of Nephrology and Hypertension, University of North Carolina, Chapel Hill, North Carolina, USA.
Raed Bou MatarCenter for Pediatric Nephrology, Cleveland Clinic Children's, Cleveland, Ohio, USA.
David T SelewskiDepartment of Pediatrics, Medical University of South Carolina, Charleston, South Carolina, USA.
Tarak SrivastavaChildren's Mercy Hospital, Kansas City, Missouri, USA.
Michelle N RheaultDivision of Pediatric Nephrology, Department of Pediatrics, University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, USA.
Amira Al-UzriDivision of Pediatric Kidney Services and Hypertension, Department of Pediatrics, Oregon Health & Science University, Portland, Oregon, USA.
Amy J KogonDivision of Nephrology, Department of Pediatrics, Children's Hospital of Philadelphia, Wynnewood, Pennsylvania, USA.
Myda KhalidJW Riley Hospital for Children, Indiana University School of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Suzanne VentoDivision of Nephrology, Department of Pediatrics, New York University School of Medicine, New York, New York, USA.
Neil S SanghaniDivision of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Brenda W GillespieDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.
Debbie S GipsonDivision of Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
Chia-Shi WangDivision of Pediatric Nephrology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
Afshin ParsaDivision of Kidney, Urologic, and Hematologic Diseases, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.
Lisa Guay-WoodfordCenter for Translational Research, Children's National Health System, Washington, DC, USA.
Louis-Philippe LaurinDivision of Nephrology, Maisonneuve-Rosemont Hospital, Department of Medicine, University of Montreal, Montreal, Quebec, Canada.
University of Michigan–Ann Arbor · USChildren's Hospital of New Orleans · USChildren's Hospital of Philadelphia · USChildren's Mercy Hospital · USChildren's National · USCleveland Clinic · USColumbia University · USEmory University · USHôpital Maisonneuve-Rosemont · CAIndiana University – Purdue University Indianapolis · USMedical University of South Carolina · USNational Institutes of Health · USNew York University · USOregon Health & Science University · USStanford University · USUniversity of Minnesota · USUniversity of North Carolina at Chapel Hill · USUniversity of Toronto · CAVanderbilt University Medical Center · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
CureGN-Penn PCCU01DK100846 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI LAWRENCE B. HOLZMAN · 2019 to 2026
$8.3M
A Novel Mobile Application for Childhood Nephrotic Syndrome ManagementK23DK118189 · NIDDK · EMORY UNIVERSITY · PI WANG, CHIA-SHI · 2019 to 2023
$941k
NCATS NIH HHS UL1 TR002548NIDDK NIH HHS K23 DK118189NIDDK NIH HHS U01 DK100846NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

introductionThe 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis recommend that patients with membranous nephropathy (MN) at risk for progression receive immunosuppressive therapy (IST), usually after 6 months of observation. A cyclophosphamide (CYC) or calcineurin inhibitor (CNI)-based regimen is recommended as first-line IST. However, the extent to which KDIGO recommendations are adopted in practice remains largely unknown.

methodsWe evaluated prescribing practice among patients with primary MN (diagnosed 2010-2018) enrolled in the Cure Glomerulonephropathy Network (CureGN) cohort study. We also evaluated the availability of testing for phospholipase A2 receptor (PLA2R) in the contemporary era.

resultsAmong 361 patients (324 adults and 37 children) with MN who were IST-naïve at biopsy and had at least 6 months of follow-up, 55% of adults and 58% of children initiated IST <6 months after biopsy. Of these, 1 in 5 had no indication for (i.e., urine protein-to-creatinine ratio [uPCR] <4 g/g) or an apparent contraindication to (i.e., an estimated glomerular filtration rate [eGFR] <30 ml/min per 1.73 m

conclusionThese findings suggest that providers are not aware of, or lack confidence in, current KDIGO guidelines for MN. Treatment patterns observed in this cohort might critically inform the drafting of planned updates to KDIGO guidelines.

Indexed as

immunosuppressionmembranous nephropathytreatment patterns

Identifiers

PMID31844809
PMCPMC6895579
OpenAlexW2973454750

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.